NADAC acquisition cost data for CIPRODEX OTIC SUSPENSION. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00065853302 | $31.80 | 2022-10-19 | Rx |
| 00078079975 | $31.80 | 2022-10-19 | Rx |
| 00065853302 | $31.80 | 2022-10-19 | Rx |
| 00078079975 | $31.80 | 2022-10-19 | Rx |
| 00065853302 | $31.80 | 2022-10-19 | Rx |
| 00078079975 | $31.80 | 2022-10-19 | Rx |
| 00065853302 | $31.80 | 2022-10-19 | Rx |
| 00078079975 | $31.80 | 2022-10-19 | Rx |
| 00065853302 | $31.80 | 2022-10-19 | Rx |
| 00078079975 | $31.80 | 2022-10-19 | Rx |
Generic: Ciprofloxacin HCl/Dexameth | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | 179,771 | N/A |
| 2020 | $12.4K | 43 | 128,036 | $34.41 |
| 2021 | $4.3M | 16,874 | 19,435 | $33.69 |
| 2022 | $6.2M | 23,371 | 18,390 | $34.67 |
| 2023 | $6.1M | 22,355 | 17,816 | $35.98 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $744.9K | 2,735 | 2,179 |
| New York | $644.8K | 2,328 | 1,686 |
| Texas | $629.8K | 2,299 | 1,928 |
| Florida | $347.5K | 1,268 | 1,092 |
| Pennsylvania | $315.0K | 1,140 | 804 |
| Michigan | $257.0K | 949 | 756 |
| Ohio | $223.3K | 821 | 631 |
| Illinois | $200.2K | 723 | 600 |
| Kentucky | $190.0K | 702 | 588 |
| North Carolina | $178.2K | 659 | 529 |
| New Jersey | $163.0K | 584 | 455 |
| Massachusetts | $146.0K | 531 | 421 |
| Georgia | $131.3K | 483 | 373 |
| Tennessee | $118.3K | 432 | 353 |
| Missouri | $112.4K | 414 | 363 |
| Indiana | $107.9K | 402 | 322 |
| Arizona | $100.9K | 372 | 299 |
| Arkansas | $100.4K | 367 | 304 |
| Louisiana | $93.6K | 351 | 306 |
| Mississippi | $90.3K | 331 | 263 |
| Virginia | $89.2K | 326 | 269 |
| Maryland | $87.4K | 317 | 249 |
| Maine | $75.0K | 265 | 232 |
| Minnesota | $74.7K | 274 | 217 |
| Connecticut | $70.9K | 261 | 226 |
| Iowa | $69.6K | 256 | 205 |
| Wisconsin | $68.2K | 249 | 203 |
| South Carolina | $56.6K | 206 | 177 |
| Nebraska | $52.7K | 194 | 153 |
| Oklahoma | $52.6K | 193 | 156 |
| West Virginia | $52.1K | 198 | 162 |
| Washington | $49.8K | 187 | 168 |
| Kansas | $49.6K | 181 | 150 |
| Colorado | $46.6K | 173 | 143 |
| Alabama | $42.9K | 156 | 136 |
| Oregon | $32.0K | 133 | 112 |
| New Hampshire | $29.4K | 106 | 98 |
| Vermont | $22.2K | 81 | 69 |
| North Dakota | $21.6K | 79 | 66 |
| Delaware | $20.9K | 78 | 65 |
| South Dakota | $19.8K | 73 | 52 |
| Idaho | $18.9K | 76 | 69 |
| Montana | $18.0K | 67 | 56 |
| District of Columbia | $16.4K | 59 | 36 |
| Nevada | $15.0K | 54 | 46 |
| Utah | $12.9K | 46 | 43 |
| New Mexico | $10.5K | 37 | 37 |
| Alaska | $8.7K | 31 | 29 |
| Rhode Island | $7.8K | 29 | 26 |
| Wyoming | $6.9K | 25 | 23 |
| Hawaii | $5.8K | 21 | 21 |
| Puerto Rico | $5.5K | 19 | 12 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.